Phase 1 Study: STX-0712 in Advanced Hematologic Malignancies

Solu Therapeutics, Inc is conducting a first-in-human, open‐label trial evaluating STX-0712 in patients with advanced CMML and AML who have exhausted available treatment options. Using a dose escalation and expansion design with administration every 21 days, the study will assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.